OFF-LABEL PROMOTION IS UNLIKELY TO PROVIDE INFORMATION BENEFIT TO PHYSICIANS, FDA's TEMPLE SAYS; SINGLE PIVOTAL STUDIES ARE "NOT CHEAPER" AND "HIGH RISK"

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".